表紙
市場調査レポート

エダラボンの中国市場

Investigation Report on China Edaravone Market, 2010-2019

発行 China Research and Intelligence 商品コード 332766
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
エダラボンの中国市場 Investigation Report on China Edaravone Market, 2010-2019
出版日: 2015年06月11日 ページ情報: 英文 30 Pages
概要

エダラボンは、中国市場に登場して以来、その売上げを急速に伸ばしています。2005年に5000万人民元にも満たなかった売上げは、その後、34.3%のCAGRで拡大し、2014年には6億2900万人民元に達しました。

当レポートでは、中国におけるエダラボン市場の規模と今後の見通し、主要製薬会社および剤形別の市場シェア、販売価格などの情報を提供しています。

第1章 エダラボンの関連概念

  • 適応
  • 世界市場における販売状況

第2章 中国におけるエダラボンの市場プロファイル

  • エダラボンの特許および承認状況
  • 主要製薬会社
  • 市場規模

第3章 中国におけるエダラボンの販売状況調査

  • 販売額
    • 総販売額
    • 地域別の販売額
  • 販売量
    • 総販売量
    • 地域別の販売数

第4章 中国におけるエダラボンの主要製薬会社の市場シェア調査

  • 販売額ベースの市場シェア
  • 販売量ベースの市場シェア

第5章 中国におけるエダラボンの剤形に関する調査

  • 剤形別の市場シェア:販売額ベース
  • 剤形別の市場シェア:販売量ベース

第6章 中国の病院におけるエダラボンの基準価格

  • Kunming Jida Pharmaceutical Co., Ltd
  • Nanjing Simcere Dongyuan Pharmaceutical Co.,Ltd.
  • Jilin Boda Pharmaceutical Co., Ltd (Yi Da Sheng)
  • Jilin Province Huinan Changlong Biopharmacy Co., Ltd (Qing Tong)
  • China National Medicines Guorui Pharmaceutical Co., Ltd
  • Science & Technology General Company Hebei Medical University (Kai Da Fu Xin)
  • Fujian Tianquan Pharmaceutical Co., Ltd
  • Shaanxi Jianmin Pharmaceutical Co., Ltd (Bai Yi Da)

第7章 中国市場におけるエダラボンの主要製薬会社

  • Jilin Boda Pharmaceutical Co., Ltd
  • Jilin Province Huinan Changlong Biopharmacy Co., Ltd
  • Nanjing Simcere Dongyuan Pharmaceutical Co.,Ltd.
  • Kunming Jida Pharmaceutical Co., Ltd
  • China National Medicines Guorui Pharmaceutical Co., Ltd

第8章 中国におけるエダラボンの市場見通し

  • 市場規模の予測
  • 競合情勢の予測
目次
Product Code: 1506209

Cerebrovascular disease is one of the three principal diseases that can cause people to death. Acute cerebral infarction which occupies 70% of cerebrovascular disease has a disability rate of 50%-70% and a recurrence rate of 40%. And one thing to be noted is that the more relapses people have, the higher the mortality and disability.

Acute cerebral infarction, one of the serious threats to old people's health, features sudden onset, complex pathogenesis and "three high and one low": high morbidity, high mortality, high fatality and low cure rate.

Edaravone injection, a life-saving drug for the treatment of acute cerebral infarction, is the only free radical scavenger in the world with a clear mechanism and target of acute cerebral infarction. Ever since its debut in Japan in 2002, its sales in the first 13 months has surpassed JPY 40 billion.

Simcere is China's first and world's second manufacturer of edaravone injection. Its new product "Bi Cun" is priced at 1/33 of the price of similar products in Japan. In 2007, "Bi Cun" spread over China with a market share of 74.62%. According to CRI's statistics, edaravone develops fast after entering China, annual sales value rising from less than CNY 50 million in 2005 to CNY 629 million in 2014 and CAGR reaching up to 34.3% during the period of 2005-2015. Currently, local manufacturers of edaravone are as follows: Simcere, Jilin Boda Pharmaceutical Co., Ltd, Jilin Province Huinan Changlong Biopharmacy Co., Ltd and Kunming Jida Pharmaceutical Co., Ltd, among which Simcere has the largest market share of 39% with sales value reaching up to CNY 246 million in 2014.

With the ageing population, the incidence of acute cerebral infarction in China will keep increasing, thus promoting the growth of edaravone market.

Readers can get at least the following information from this report:

  • market size of edaravone in China
  • market share of manufacturers of edaravone in China
  • price of edaravone in Chinese market
  • major manufacturers of edaravone in Chinese market
  • market outlook of edaravone in China

The author suggests the following groups of people purchase this report:

  • manufacturers of cerebrovascular drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Edaravone

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Edaravone in China

  • 2.1. Patent and Approval Status of Edaravone in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Edaravone in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Edaravone in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Edaravone in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Edaravone in Chinese Hospitals in 2014

  • 6.1. Kunming Jida Pharmaceutical Co., Ltd
  • 6.2. Nanjing Simcere Dongyuan Pharmaceutical Co.,Ltd.
  • 6.3. Jilin Boda Pharmaceutical Co., Ltd (Trade Name: Yi Da Sheng)
  • 6.4. Jilin Province Huinan Changlong Biopharmacy Co., Ltd (Trade Name: Qing Tong)
  • 6.5. China National Medicines Guorui Pharmaceutical Co., Ltd
  • 6.6. Science & Technology General Company Hebei Medical University (Trade Name: Kai Da Fu Xin)
  • 6.7. Fujian Tianquan Pharmaceutical Co., Ltd
  • 6.8. Shaanxi Jianmin Pharmaceutical Co., Ltd (Trade Name: Bai Yi Da)

7. Major Manufacturers of Edaravone in Chinese Market, 2010-2014

  • 7.1. Jilin Boda Pharmaceutical Co., Ltd
  • 7.2. Jilin Province Huinan Changlong Biopharmacy Co., Ltd
  • 7.3. Nanjing Simcere Dongyuan Pharmaceutical Co.,Ltd.
  • 7.4. Kunming Jida Pharmaceutical Co., Ltd
  • 7.5. China National Medicines Guorui Pharmaceutical Co., Ltd

8. Market Outlook of Edaravone in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Approval Information of Edaravone in China
  • Chart Sales Status of Edaravone in China, 2010-2014
  • Chart Sales Value of Edaravone in China, 2010-2014
  • Chart Sales Value of Edaravone in Some Regions in China, 2010-2014
  • Chart Sales Volume of Edaravone in China, 2010-2014
  • Chart Market Share of TOP5 Manufacturers of Edaravone for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Edaravone Made by Simcere in China, 2010-2014
  • Chart Sales Value and Market Share of Edaravone Made by Jilin Boda in China, 2010-2014
  • Chart Sales Value and Market Share of Edaravone Made by Kunming Jida in China, 2010-2014
  • Chart Sales Value and Market Share of Edaravone Made by Huinan Changlong in China, 2010-2014
  • Chart Sales Value and Market Share of Edaravone Made by Guorui in China, 2010-2014
  • Chart Sales Value and Market Share of Edaravone Injection in China, 2010-2014
  • Chart Price of Edaravone Made by Kunming Jida Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Edaravone Made by Simcere in Some Chinese Cities in 2014
  • Chart Price of Edaravone Made by Jilin Boda Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Edaravone Made by Jilin Province Huinan Changlong Biopharmacy Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Edaravone Made by China National Medicines Guorui Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Back to Top